Clinical Trials Logo
  1. Home
  2. Breakthrough Cancer Pain
  3. NCT00822614

Safety of Fentanyl TAIFUN Treatment — FINDS  

Breakthrough Cancer Pain Clinical Trial

Official title:
The Safety of Fentanyl TAIFUN Treatment After Titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients

Clinical Trial Summary

A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group Trial to Evaluate hte Safety of Fentanyl TAIFUN Treatment after titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients on Maintenance Opioid Therapy

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00822614
Study type Interventional
Source Akela Pharma, Inc.
Contact Donna J Fordham
Phone 941 742 6585
Email fordhamd@akelapharma.com
Status Recruiting
Phase Phase 3
Start date December 2008
Completion date January 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Recruiting NCT01698645 - Patient Satisfaction and Quality of Life Impact - PecFent® N/A
Recruiting NCT01693328 - Patient Satisfaction and Quality of Life Impact - PecFent® N/A
Completed NCT01936636 - Observational Registry Study of Quality of Life When Treating BTcP With Abstral N/A
Completed NCT05531422 - Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP Phase 2
Completed NCT03669263 - A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan N/A
Completed NCT02899884 - Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
Recruiting NCT03564548 - Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain Phase 2
Not yet recruiting NCT04713189 - Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain Phase 1/Phase 2
Completed NCT03895762 - Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
Terminated NCT01439919 - A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain Phase 2
Completed NCT01045603 - Instanyl® Non-Interventional Study N/A
Terminated NCT04468490 - Treatment of Breakthrough Cancer Pain According to European Guidelines